Published in Future Oncol on September 14, 2016
The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. J Cancer (2017) 0.75
Obesity and metabolic dysfunction severely influence prostate cell function: role of insulin and IGF1. J Cell Mol Med (2017) 0.75
BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people. Oncotarget (2017) 0.75
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA (2003) 25.44
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med (2004) 6.16
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med (2011) 6.15
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Dietary fat intake does affect obesity! Am J Clin Nutr (1998) 4.26
Obesity and cancer. Oncologist (2010) 3.01
Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol (2013) 2.57
Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis (2006) 2.48
Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem (2003) 2.38
Cholesteryl ester accumulation induced by PTEN loss and PI3K/AKT activation underlies human prostate cancer aggressiveness. Cell Metab (2014) 2.35
Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control (2006) 2.29
Obesity as a major risk factor for cancer. J Obes (2013) 2.26
Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun (2016) 2.22
Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2011) 2.19
Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res (2002) 2.11
Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst (1997) 1.98
Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol (2012) 1.97
Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One (2012) 1.89
Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer (2003) 1.87
Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res (2004) 1.81
Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.77
Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer (2004) 1.73
Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology (2001) 1.65
Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol (2007) 1.63
Prostate cancer and adiponectin. Urology (2005) 1.59
Insulin receptor expression by human prostate cancers. Prostate (2009) 1.57
Oleate activates phosphatidylinositol 3-kinase and promotes proliferation and reduces apoptosis of MDA-MB-231 breast cancer cells, whereas palmitate has opposite effects. Cancer Res (2000) 1.55
Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst (2007) 1.53
Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol (2000) 1.50
The fat side of prostate cancer. Biochim Biophys Acta (2013) 1.46
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int (2012) 1.46
The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle (2010) 1.42
Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res (2011) 1.37
Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol (2004) 1.28
The G-protein-coupled receptor 40 family (GPR40-GPR43) and its role in nutrient sensing. Biochem Soc Trans (2006) 1.25
Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs (2010) 1.23
Fat intake after diagnosis and risk of lethal prostate cancer and all-cause mortality. JAMA Intern Med (2013) 1.22
Prostate cancer cell proliferation is influenced by leptin. J Surg Res (2004) 1.22
Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem (2003) 1.20
Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. Nutr Cancer (2008) 1.16
Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk. Clin Cancer Res (2009) 1.13
Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer (2003) 1.10
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One (2013) 1.09
Anthropometry and prostate cancer risk: a prospective study of 22,248 Norwegian men. Cancer Causes Control (1999) 1.09
New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK. Clin Cancer Res (2010) 1.06
A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J Pathol (2010) 1.05
Predicting Pathological Features at Radical Prostatectomy in Patients with Prostate Cancer Eligible for Active Surveillance by Multiparametric Magnetic Resonance Imaging. PLoS One (2015) 1.02
Aromatase up-regulation, insulin and raised intracellular oestrogens in men, induce adiposity, metabolic syndrome and prostate disease, via aberrant ER-α and GPER signalling. Mol Cell Endocrinol (2012) 1.00
Periprostatic fat correlates with tumour aggressiveness in prostate cancer patients. BJU Int (2010) 1.00
Obesity and obstructive sleep apnea-hypopnea syndrome. Obes Rev (2008) 1.00
Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol (2004) 0.99
Metabolomic profiling for the identification of novel diagnostic markers in prostate cancer. Expert Rev Mol Diagn (2015) 0.98
The epidemiology of prostate cancer part II: the risk factors. Semin Urol Oncol (1998) 0.98
Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology (2004) 0.98
Obesity Statistics. Prim Care (2016) 0.95
New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets (2012) 0.91
Mitogenic and anti-apoptotic actions of adipocyte-derived hormone leptin in prostate cancer cells. BJU Int (2008) 0.91
Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Urol Oncol (2015) 0.89
Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta (2012) 0.89
Arachidonic acid promotes FAK activation and migration in MDA-MB-231 breast cancer cells. Exp Cell Res (2008) 0.89
Oleic acid promotes migration on MDA-MB-231 breast cancer cells through an arachidonic acid-dependent pathway. Int J Biochem Cell Biol (2009) 0.88
Sipuleucel-T for prostate cancer: the immunotherapy era has commenced. Expert Rev Anticancer Ther (2011) 0.88
Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer. Ann Oncol (2010) 0.87
Combined magnetic resonance spectroscopy and dynamic contrast-enhanced imaging for prostate cancer detection. Urol Oncol (2011) 0.83
Body mass index and mortality in men with prostate cancer. Prostate (2015) 0.83
The role of dietary fat throughout the prostate cancer trajectory. Nutrients (2014) 0.83
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncol (2015) 0.83
Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice. Eur Urol (2010) 0.82
Tumor cell-educated periprostatic adipose tissue acquires an aggressive cancer-promoting secretory profile. Cell Physiol Biochem (2012) 0.81
Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38. Autophagy (2015) 0.80
Associations between unprocessed red and processed meat, poultry, seafood and egg intake and the risk of prostate cancer: A pooled analysis of 15 prospective cohort studies. Int J Cancer (2016) 0.80
Fatty acids, eicosanoids and PPAR gamma. Eur J Pharmacol (2015) 0.79
Fat intake after prostate cancer diagnosis and mortality in the Physicians' Health Study. Cancer Causes Control (2015) 0.78
Biomarkers in localized prostate cancer. Future Oncol (2016) 0.78
Effects of oleic acid on cell proliferation through an integrin-linked kinase signaling pathway in 786-O renal cell carcinoma cells. Oncol Lett (2013) 0.78
Endogenous and exogenous testosterone and the risk of prostate cancer and increased prostate-specific antigen (PSA) level: a meta-analysis. BJU Int (2016) 0.77
Soluble interleukin-6 receptor to interleukin-6 (sIL‑6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy. Oncol Lett (2011) 0.77
Total testosterone levels are correlated to metabolic syndrome components. Aging Male (2016) 0.77
A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. Nutr J (2015) 0.76
Preclinical models relevant to diet, exercise, and cancer risk. Recent Results Cancer Res (2005) 0.76
Conjugated linoleate reduces prostate cancer viability whereas the effects of oleate and stearate are cell line-dependent. Anticancer Res (2013) 0.75
Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy. Urol Oncol (2015) 0.94
Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Urol Oncol (2015) 0.89
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. Future Oncol (2015) 0.83
PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance. World J Urol (2015) 0.82
Metabolic syndrome, obesity, and radical cystectomy complications: a clavien classification system-based analysis. Clin Genitourin Cancer (2014) 0.78
Biomarkers in localized prostate cancer. Future Oncol (2016) 0.78